Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
24 participants
INTERVENTIONAL
2026-01-01
2026-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be assessed for the genital, mucosal and systemic safety and pharmacokinetics of KB15A in a preliminary single-dose phase of the study, where they will receive two single doses of either KB15A or placebo vaginal film, and again in a multiple-dose phase of the study, where they will receive 14 daily doses of either KB15A or placebo vaginal film.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will determine whether the KB15A film is safe in healthy women 18 - 45 years of age; it will also determine where the KB15A antibody is distributed in the body after film use. Participants must not be at risk of pregnancy due to one of the following approved methods of contraception or abstinence:
* prior surgical sterilization of self or sexual partner
* oral contraceptive pills
* transdermal patch
* contraceptive injection
* hormonal intrauterine system (IUS)
* heterosexual abstinence, or
* copper intrauterine device
Participants will be assessed for the genital, mucosal and systemic safety and pharmacokinetics of KB15A in two sequential study phases, separated by an approximately 2 - 6 week wash out period:
1. A preliminary single-dose phase of the study where participants will receive two single doses of either KB15A or placebo vaginal film, separated by approximately 1 week;
2. A multiple-dose phase of the study where participants will receive 14 consecutive daily doses of either KB15A or placebo vaginal film.
For the primary objective of the study, participants will be evaluated for Treatment Emergent Adverse Events (TEAEs) and relatedness of TEAEs to study product or study procedures, changes in colposcopic findings, and changes in systemic laboratories (e.g. complete blood count, chemistry panel) after two single doses in the single dose phase, and again after 14 daily doses in the multiple dose phase.
The secondary objective of the study is to describe the concentration of monoclonal antibody locally in the cervicovaginal mucosa, and systemically in the blood. Pharmacokinetics will be measured at baseline and at 30 minutes and 1, 2, and 4 hours after the first single dose; at 30 minutes and 8 or 48 hours after the second single dose (depending on the pharmacokinetic sampling time point randomization assignment); at 1, 4, 8, and 24 hours after the 1st dose of film in the multiple dose phase; and 24 hours after the 14th dose in the multiple dose phase. Finally, pharmacokinetics will be measured 5 - 8 days after the 14th dose of the film in the multiple-dose phase.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KB15A
KB15A (Vaginal Film)
KB15A Vaginal Film
KB15A is a polyvinyl-alcohol based intravaginal film containing the KB15A.16.2 monoclonal antibody.
Placebo
Placebo (Vaginal Film)
Placebo Vaginal Film
The Placebo is a polyvinyl-alcohol based intravaginal film composed identically to the KB15A Vaginal Film, but without the KB15A.16.2 monoclonal antibody.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KB15A Vaginal Film
KB15A is a polyvinyl-alcohol based intravaginal film containing the KB15A.16.2 monoclonal antibody.
Placebo Vaginal Film
The Placebo is a polyvinyl-alcohol based intravaginal film composed identically to the KB15A Vaginal Film, but without the KB15A.16.2 monoclonal antibody.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* General good health (by volunteer history and per investigator judgment) without any clinically significant systemic disease (including, but not limited to significant liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or bone disease, and diabetes) and with an intact gastrointestinal tract, uterus and cervix.
* History of regular menstrual cycles, by volunteer report, if not taking exogenous hormones
* History of Pap smears and follow-up consistent with standard clinical practice as outlined in the Study Manual or willing to undergo a Pap smear at Visit 1
* Willing to give voluntary consent and sign an informed consent form.
* Willing to use non-spermicidal, lubricated condoms for any vaginal intercourse according to the study protocol.
* Willing to abstain from intercourse and use of intravaginal medications, lubricants, and other products as required in the protocol.
* Vaginal and cervical anatomy that, in the opinion of the investigator, lends itself to easy genital tract sample collection.
* Must be protected from pregnancy by:
* Sterilization of either partner
* Heterosexual abstinence
* Hormonal contraceptives (except for the contraceptive vaginal ring)
* Copper IUD
* If in a relationship, must be in a mutually monogamous relationship with a partner who is not known to be HIV positive and has no known risk of sexually transmitted infections (STIs)
Exclusion Criteria
* Currently pregnant
* Currently breastfeeding or planning to breastfeed during the course of the study
* Current Positive test for Trichomonas vaginalis, Neisseria gonorrhea, Chlamydia trachomatis,
* Current symptomatic bacterial vaginosis (BV)
* Chronic or acute vulvar or vaginal symptoms (pain, irritation, spotting/bleeding, discharge, etc.)
* Significant gynecological abnormalities (including abnormal vaginal bleeding, excessive vaginal discharge, or vulvar/vaginal pain or irritation)
* Current symptomatic UTI or vaginal candidiasis
* History of sensitivity/allergy to KB15A film components, for either the volunteer
* Less than 14 days since use of oral or vaginal antibiotics
* Women with a history of genital herpes or condylomata who have been symptomatic in the last six months.
* Deep epithelial genital findings such as abrasions, ulcerations, and lacerations, or vesicles suspicious for an STI
* Known current drug or alcohol abuse which could affect study compliance.
* Participation in any other investigational trial within the last 30 days or planned participation in any other investigational trial during the study
* History of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix within the last 14 days
* Abnormal finding on laboratory or physical examination or a social or medical condition in the participant, which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data.
* Grade 2 or higher laboratory abnormality, per the 2014 update of the Division of AIDS, National Institute of Allergy and Infectious Disease (DAIDS) Table for Grading the Severity of Adverse Events, or clinically significant laboratory abnormality as determined by the clinician.
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Boston University
OTHER
Old Dominion University
OTHER
ZabBio Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Virginia Health Sciences at Old Dominion University
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KB15A-01
Identifier Type: -
Identifier Source: org_study_id